Cornelis P Van Der Logt

Title: Cornelis P Van Der Logt: Innovator in Antibody Fragment Technology

Introduction

Cornelis P Van Der Logt is a notable inventor based in Bedford, GB. He has made significant contributions to the field of biotechnology, particularly in the development of antibody fragments. With a total of five patents to his name, Van Der Logt's work has advanced the understanding and application of immunoglobulin technology.

Latest Patents

Among his latest patents is a method for producing antibody fragments. This innovative approach involves an expression library that comprises a repertoire of nucleic acid sequences cloned from a non-immunised source. Each sequence encodes at least part of a variable domain of a heavy chain derived from an immunoglobulin that is naturally devoid of light chains (VHH). The library enhances sequence variability by introducing mutations in the complementarity determining regions (CDRs) or by generating alternative combinations of CDR and framework sequences not naturally present in the naïve library repertoire. This library is particularly useful in preparing antibodies, especially antibody fragments. Another significant patent involves multivalent antigen-binding proteins, which consist of a single polypeptide chain comprising two or more single domain binding units, preferably heavy chain variable domains derived from immunoglobulins devoid of light chains. The methods for their production and uses, particularly in diagnosis, immunoassay, and purification methods, are also disclosed.

Career Highlights

Cornelis P Van Der Logt has worked with prominent companies in the industry, including Unilever Patent Holdings B.V. and Quest International B.V. His experience in these organizations has contributed to his expertise in patent development and biotechnology.

Collaborations

Some of his notable coworkers include Paul James Davis and Leon Frenken. Their collaborative efforts have likely played a role in advancing the projects they have worked on together.

Conclusion

Cornelis P Van Der Logt's innovative work in antibody fragment technology and his contributions to the biotechnology field are commendable. His patents reflect a deep understanding of immunoglobulin technology and its applications.